FY2025 · ended Dec 31, 2025 · Revenue $19.09M · Filed Mar 24, 2026
Lenz Therapeutics, Inc. (LENZ) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $19.1 million and a net loss of $82.1 million. Free cash flow was -$70.0 million. As of Sep 30, 2026 it held $30.6 million in cash and investments and $460,000 in total debt.
Revenue (TTM)
$12.36M
Net income (TTM)
$-140.27M
-138.2% vs year-ago TTM
Operating cash flow (TTM)
$-127.63M
-182.2% vs year-ago TTM
Free cash flow (TTM)
$-127.70M
-176.6% vs year-ago TTM
EPS (TTM)
$-4.48
-112.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.35M
+13.8% vs prior year
Net cash
$30.09M
as of Sep 30, 2026
Operating margin
-1211.2%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LENZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815776
- Former names
- Graphite Bio, Inc. (until Mar 19, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $19.1M | — | — | — | — |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M |
| Net income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M |
| Diluted EPS | -$2.85 | -$2.34 | -$35.71 | -$1.84 | — |
| Operating cash flow | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M |
| Free cash flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M |
| Total assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M |
| Total liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M |
| Stockholders' equity | $284.3M | $204.1M | -$92.7M | -$24.2M | $384.1M |
| Cash and investments | $25.2M | $20.2M | $35.1M | $283.6M | $377.0M |
| Total debt | $815,000 | $1.3M | $362,000 | $5.8M | $11.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 12, 2026 |
All 358 Lenz Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.